Analyst Price Targets — MYGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 12:58 pm | Lu Li | UBS | $6.00 | $4.71 | TheFly | Myriad Genetics price target lowered to $6 from $8 at UBS |
| November 4, 2025 12:36 pm | Lu Li | UBS | $8.00 | $8.18 | TheFly | Myriad Genetics price target raised to $8 from $6 at UBS |
| May 7, 2025 1:14 pm | Bill Bonello | Craig-Hallum | $18.00 | $7.27 | TheFly | Myriad Genetics price target lowered to $18 from $29 at Craig-Hallum |
| May 7, 2025 12:18 pm | Lu Li | UBS | $7.00 | $7.27 | TheFly | Myriad Genetics price target lowered to $7 from $16 at UBS |
| May 7, 2025 10:45 am | Brandon Couillard | Wells Fargo | $6.00 | $7.27 | TheFly | Myriad Genetics downgraded to Equal Weight from Overweight at Wells Fargo |
| March 12, 2025 9:17 am | — | Piper Sandler | $12.50 | $10.41 | TheFly | Myriad Genetics upgraded to Overweight from Neutral at Piper Sandler |
| March 4, 2025 11:31 am | — | Piper Sandler | $11.50 | $10.42 | TheFly | Myriad Genetics price target lowered to $11.50 from $14 at Piper Sandler |
| December 9, 2024 11:07 am | Puneet Souda | Leerink Partners | $21.00 | $15.15 | StreetInsider | Leerink Partners Downgrades Myriad Genetics (MYGN) to Market Perform |
| October 14, 2024 10:25 am | Sung Ji Nam | Scotiabank | $34.00 | $24.67 | StreetInsider | Scotiabank Reiterates Sector Outperform Rating on Myriad Genetics (MYGN) |
| September 19, 2024 5:04 am | Tejas Savant | Morgan Stanley | $32.00 | $28.47 | TheFly | Myriad Genetics initiated with an Equal Weight at Morgan Stanley |
Latest News for MYGN
Myriad Genetics, Inc. MYGN is well-placed for growth in the coming quarters due to its steady rollout of new testing panels and product enhancements. The company is also progressing in its Cancer Care Continuum strategy, supported by rising demand in hereditary cancer and a 2026 launch calendar.
New published data shows Prolaris Biopsy Test adds significant prognostic information beyond conventional clinical risk categories for prostate cancer.
Myriad (MYGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD
MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MYGN.
U.S. House Trading
No House trades found for MYGN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.